Advanced search
Publication Cover
OncoImmunology Volume 13, 2024 - Issue 1
Submit an article Journal homepage
646
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors

Douglas C. Chunga Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada;b Department of Immunology, University of Toronto, Toronto, ON, CanadaORCID Iconhttps://orcid.org/0000-0001-7971-3051View further author information
ORCID Icon,
Maryam Ghaedia Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Kathrin Warnera Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Azin Sayada Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Samuel D. Saibila Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Marcus Q. Bernardinic Division of Gynecologic Oncology, University Health Network, Toronto, ON, CanadaORCID Iconhttps://orcid.org/0000-0001-7022-8308View further author information
ORCID Icon,
Blaise A. Clarkec Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada;d Department of Laboratory Medicine and Pathobiology, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Patricia A. Shawc Division of Gynecologic Oncology, University Health Network, Toronto, ON, CanadaView further author information
,
Marcus O. Butlera Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaORCID Iconhttps://orcid.org/0000-0002-9840-7057View further author information
ORCID Icon,
Alexandra Eassone Department of Surgical Oncology, University Health Network, Toronto, ON, CanadaView further author information
,
Sorana Morrissyf Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;g The Riddell Centre for Cancer Immunotherapy, Arnie Charbonneau Cancer Research Institute, Calgary, AB, CanadaORCID Iconhttps://orcid.org/0000-0001-8526-562XView further author information
ORCID Icon,
Ben X. Wanga Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Linh Nguyena Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, CanadaView further author information
,
Pamela S. Ohashia Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada;b Department of Immunology, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2915-9317View further author information
ORCID Icon &
Nicolas Jacquelotf Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;g The Riddell Centre for Cancer Immunotherapy, Arnie Charbonneau Cancer Research Institute, Calgary, AB, Canada;h Department of Microbiology, Immunology and Infectious Disease, Cumming School of Medicine, University of Calgary, Calgary, AB, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0282-1892View further author information
ORCID Icon show all
Article: 2349347 | Received 14 Jul 2023, Accepted 25 Apr 2024, Published online: 10 May 2024

References

  • Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–17. doi:10.1038/nrclinonc.2017.101.
  • Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245.
  • Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Flores C, Chen L, Kwon BS, Borg C. et al. Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis. J Invest Dermatol. 2016;136(5):994–1001. doi:10.1016/j.jid.2015.12.042.
  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093.
  • Ceci C, Atzori MG, Lacal PM, Graziani G. Targeting tumor-associated macrophages to increase the efficacy of immune checkpoint inhibitors: a glimpse into novel therapeutic approaches for metastatic melanoma. Cancers. 2020;12(11):3401. doi:10.3390/cancers12113401.
  • Schweer D, McAtee A, Neupane K, Richards C, Ueland F, Kolesar J. Tumor-associated macrophages and ovarian cancer: implications for therapy. Cancers. 2022;14(9):2220. doi:10.3390/cancers14092220.
  • Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310. doi:10.3389/fimmu.2018.01310.
  • Jacquelot N, Pitt JM, Enot DP, Roberti MP, Duong CPM, Rusakiewicz S, Eggermont AM, Zitvogel L. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology. 2017;6(8):e1299303. doi:10.1080/2162402X.2017.1299303.
  • Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565. doi:10.1038/s41586-019-1914-8.
  • Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH. CD20+ tumor-infiltrating lymphocytes have an Atypical CD27– memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281–3292. doi:10.1158/1078-0432.CCR-12-0234.
  • Kroeger DR, Milne K, Nelson BH. Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-Cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res. 2016;22(12):3005–3015. doi:10.1158/1078-0432.CCR-15-2762.
  • Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, Patterson JW, Slingluff CL. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070–1080. doi:10.1158/0008-5472.CAN-11-3218.
  • Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–213. doi:10.1056/NEJMoa020177.
  • Huuhtanen J, Hakanen, HH, Lönnberg, T, Dufva, O, Peltola, K, Mäkelä, S, Hernberg, M, Bono, P, Anna, K and Mustjoki, S. Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients. J Clin Invest. 2023;e164809. doi:10.1172/JCI164809.
  • Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T. et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 2018;6(1):139. doi:10.1186/s40425-018-0446-3.
  • Vieyra-Lobato MR, Vela-Ojeda J, Montiel-Cervantes L, López-Santiago R, Moreno-Lafont MC. Description of CD8+ regulatory T lymphocytes and their specific intervention in graft-versus-host and infectious diseases, autoimmunity, and cancer. J Immunol Res. 2018;2018:e3758713. doi:10.1155/2018/3758713.
  • Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P. et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti–PD-1 treatment. Clin Cancer Res. 2018;24(13):3036–3045. doi:10.1158/1078-0432.CCR-17-2257.
  • Park SL, Gebhardt T, Mackay LK. Tissue-resident memory T cells in cancer immunosurveillance. Trends Immunol. 2019;40(8):735–747. doi:10.1016/j.it.2019.06.002.
  • Webb JR, Milne K, Watson P, deLeeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(2):434–444. doi:10.1158/1078-0432.CCR-13-1877.
  • Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022;40(5):545–557.e13. doi:10.1016/j.ccell.2022.03.008.
  • Zhang S, Chopin M, Nutt SL. Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy. Trends Immunol. 2021;42(12):1113–1127. doi:10.1016/j.it.2021.10.004.
  • Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA. et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity. Cell. 2019;177(3):556–571.e16. doi:10.1016/j.cell.2019.02.005.
  • Zhou B, Lawrence T, Liang Y. The role of plasmacytoid dendritic cells in cancers. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.749190.
  • Jacquelot N, Seillet C, Vivier E, Belz GT. Innate lymphoid cells and cancer. Nat Immunol. 2022;23(3):371–379. doi:10.1038/s41590-022-01127-z.
  • Chiossone L, Dumas P-Y, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671–688. doi:10.1038/s41577-018-0061-z.
  • Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi A-S. et al. ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916–2929. doi:10.1172/JCI89717.
  • Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C. et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8(1):593. doi:10.1038/s41467-017-00678-2.
  • Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE. et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054–1066. doi:10.1016/j.cell.2018.07.017.
  • Cherrier M, Ramachandran G, Golub R. The interplay between innate lymphoid cells and T cells. Mucosal Immunol. 2020;13(5):732–742. doi:10.1038/s41385-020-0320-8.
  • Seillet C, Jacquelot N. Sensing of physiological regulators by innate lymphoid cells. Cell Mol Immunol. 2019;16(5):442–451. doi:10.1038/s41423-019-0217-1.
  • Chung DC, Jacquelot N, Ghaedi M, Warner K, Ohashi PS. Innate lymphoid cells: role in immune regulation and cancer. Cancers Basel. 2022;14(9):2071. doi:10.3390/cancers14092071.
  • Flores-Borja F, Irshad S, Gordon P, Wong F, Sheriff I, Tutt A, Ng T. Crosstalk between innate lymphoid cells and other immune cells in the tumor microenvironment. J Immunol Res. 2016;2016:1–14. doi:10.1155/2016/7803091.
  • Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, Grisaru-Tal S, Louis C, Huang Q, Schreuder J. et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22(7):851–864. doi:10.1038/s41590-021-00943-z.
  • Garofalo C, Cerantonio A, Muscoli C, Mollace V, Viglietto G, De Marco C, Cristiani CM. Helper innate lymphoid cells – unappreciated players in melanoma therapy. Cancers. 2023;15(3):933. doi:10.3390/cancers15030933.
  • Jacquelot N, Ghaedi M, Warner K, Chung DC, Crome SQ, Ohashi PS. Immune checkpoints and innate lymphoid cells – new avenues for cancer immunotherapy. Cancers Basel. 2021;13(23):5967. doi:10.3390/cancers13235967.
  • Mariotti FR, Quatrini L, Munari E, Vacca P, Moretta L. Innate lymphoid cells: expression of PD-1 and other checkpoints in normal and pathological conditions. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.00910.
  • Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ. et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18(9):1004–1015. doi:10.1038/ni.3800.
  • Merino A, Zhang B, Dougherty P, Luo X, Wang J, Blazar BR, Miller JS, Cichocki F. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J Clin Invest. 2019;129(9):3770–3785. doi:10.1172/JCI125916.
  • Seillet C, Mielke L, Amann-Zalcenstein D, Su S, Gao J, Almeida F, Shi W, Ritchie M, Naik S, Huntington N. et al. Deciphering the innate lymphoid cell transcriptional program. Cell Rep. 2016;17(2):436–447. doi:10.1016/j.celrep.2016.09.025.
  • Yu Y, Tsang JCH, Wang C, Clare S, Wang J, Chen X, Brandt C, Kane L, Campos LS, Lu L. et al. Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway. Nature. 2016;539(7627):102–106. doi:10.1038/nature20105.
  • Salimi M, Wang R, Yao X, Li X, Wang X, Hu Y, Chang X, Fan P, Dong T, Ogg G. et al. Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer. 2018;18(1):341. doi:10.1186/s12885-018-4262-4.
  • Cristiani CM, Capone M, Garofalo C, Madonna G, Mallardo D, Tuffanelli M, Vanella V, Greco M, Foti DP, Viglietto G. et al. Altered frequencies and functions of innate lymphoid cells in melanoma patients are modulated by immune checkpoints inhibitors. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.811131.
  • Shen C, Liu C, Zhang Z, Ping Y, Shao J, Tian Y, Yu W, Qin G, Liu S, Wang L. et al. PD-1 affects the Immunosuppressive function of group 2 innate lymphoid cells in human non-small cell lung cancer. Front Immunol. 2021;12. doi:10.3389/fimmu.2021.680055.
  • Taylor S, Huang Y, Mallett G, Stathopoulou C, Felizardo TC, Sun M-A, Martin EL, Zhu N, Woodward EL, Elias MS. et al. PD-1 regulates KLRG1+ group 2 innate lymphoid cells. J Exp Med. 2017;214(6):1663–1678. doi:10.1084/jem.20161653.
  • Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D. et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579(7797):130–135. doi:10.1038/s41586-020-2015-4.
  • Helou DG, Shafiei-Jahani P, Lo R, Howard E, Hurrell BP, Galle-Treger L, Painter JD, Lewis G, Soroosh P, Sharpe AH. et al. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity. Nat Commun. 2020;11(1):3998. doi:10.1038/s41467-020-17813-1.
  • Wu D, Hu L, Han M, Deng Y, Zhang Y, Ren G, Zhao X, Li Z, Li P, Zhang Y. et al. PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation. Nat Metab. 2022;4(7):867–882. doi:10.1038/s42255-022-00595-9.
  • Grzywacz B, Kataria N, Verneris MR. CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007;21(2):356–359. doi:10.1038/sj.leu.2404499.
  • Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia. 2005;19(5):835–840. doi:10.1038/sj.leu.2403704.
  • Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, Zimmer J. Human CD56bright NK cells: an update. J Immunol. 2016;196(7):2923–2931. doi:10.4049/jimmunol.1502570.
  • Krabbendam L, Heesters BA, Kradolfer CMA, Spits H, Bernink JH. Identification of human cytotoxic ILC3s. Eur J Immunol. 2021;51(4):811–823. doi:10.1002/eji.202048696.
  • Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L. et al. Systemic human ILC precursors provide a substrate for tissue ILC differentiation. Cell. 2017;168(6):1086–1100.e10. doi:10.1016/j.cell.2017.02.021.
  • Nagasawa M, Heesters BA, Kradolfer CMA, Krabbendam L, Martinez-Gonzalez I, de Bruijn MJW, Golebski K, Hendriks RW, Stadhouders R, Spits H. et al. KLRG1 and NKp46 discriminate subpopulations of human CD117+CRTH2– ILCs biased toward ILC2 or ILC3. J Exp Med. 2019;216(8):1762–1776. doi:10.1084/jem.20190490.
  • Spits H, Mjösberg J. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol. 2022;22(11):701–712. doi:10.1038/s41577-022-00704-5.
  • Hochdörfer T, Winkler C, Pardali K, Mjösberg J. Expression of c-Kit discriminates between two functionally distinct subsets of human type 2 innate lymphoid cells. Eur J Immunol. 2019;49(6):884–893. doi:10.1002/eji.201848006.
  • Bernink JH, Ohne Y, Teunissen MBM, Wang J, Wu J, Krabbendam L, Guntermann C, Volckmann R, Koster J, van Tol S. et al. C-kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies. Nat Immunol. 2019;20(8):992–1003. doi:10.1038/s41590-019-0423-0.
  • Falquet M, Ercolano G, Jandus P, Jandus C, Trabanelli S. Healthy and patient type 2 innate lymphoid cells are differently affected by in vitro culture conditions. J Asthma Allergy. 2021;14:773–783. doi:10.2147/JAA.S304126.
  • Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19(10):599–613. doi:10.1038/s41577-019-0194-8.
  • Mortha A, Burrows K. Cytokine networks between innate lymphoid cells and myeloid cells. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.00191.
  • Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer. 2005;104(6):1246–1254. doi:10.1002/cncr.21283.
  • Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360–3365. doi:10.1073/pnas.0611533104.
  • Miracco C, Mourmouras V, Biagioli M, Rubegni P, Mannucci S, Monciatti I, Cosci E, Tosi P, Luzi P. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep. 2007;18:1115–1122.
  • Salmi S, Siiskonen H, Sironen R, Tyynelä-Korhonen K, Hirschovits-Gerz B, Valkonen M, Auvinen P, Pasonen-Seppänen S. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma. Melanoma Res. 2019;29(3):237–247. doi:10.1097/CMR.0000000000000522.
  • Tan Q, Liu H, Xu J, Mo Y, Dai F. Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer. Aging (Albany NY). 2021;13(19):23210–23232. doi:10.18632/aging.203613.
  • Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T, Seki S, Hayakawa M. Induction of CD16 + CD56 bright NK cells with antitumour cytotoxicity not only from CD16 – CD56 bright NK cells but also from CD16 – CD56 dim NK cells: CD16 – CD56 dim/bright and CD16 + CD56 bright NK cells. Scand J Immunol. 2007;65(2):126–138. doi:10.1111/j.1365-3083.2006.01883.x.
  • Vujanovic L, Chuckran C, Lin Y, Ding F, Sander CA, Santos PM, Lohr J, Mashadi-Hossein A, Warren S, White A. et al. CD56dim CD16 – natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.00014.
  • Vazquez J, Chavarria M, Lopez GE, Felder MA, Kapur A, Romo Chavez A, Karst N, Barroilhet L, Patankar MS, Stanic AK. et al. Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients. Am J Reprod Immunol. 2020;84(3):e13284. doi:10.1111/aji.13284.
  • Ercolano G, Garcia-Garijo A, Salomé B, Gomez-Cadena A, Vanoni G, Mastelic-Gavillet B, Ianaro A, Speiser DE, Romero P, Trabanelli S. et al. Immunosuppressive mediators impair proinflammatory innate lymphoid cell function in human malignant melanoma. Cancer Immunol Res. 2020;8(4):556–564. doi:10.1158/2326-6066.CIR-19-0504.
  • Wu T-C, Xu K, Banchereau R, Marches F, Yu CI, Martinek J, Anguiano E, Pedroza-Gonzalez A, Snipes GJ, O’Shaughnessy J. et al. Reprogramming tumor-infiltrating dendritic cells for CD103+CD8+ mucosal T-cell differentiation and breast cancer rejection. Cancer Immunol Res. 2014;2(5):487–500. doi:10.1158/2326-6066.CIR-13-0217.
  • Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B. et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun. 2017;8(1):15221. doi:10.1038/ncomms15221.
  • Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954.
  • Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346–1358. doi:10.1038/s41590-020-0769-3.
  • Teijeira A, Garasa S, Luri-Rey C, de Andrea C, Gato M, Molina C, Kaisho T, Cirella A, Azpilikueta A, Wculek SK. et al. Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy. Cancer Res. 2022;82(23):4373–4385. doi:10.1158/0008-5472.CAN-22-1046.
  • Zhang M, Yang W, Wang P, Deng Y, Dong Y-T, Liu F-F, Huang R, Zhang P, Duan Y-Q, Liu X-D. et al. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat Commun. 2020;11(1):6119. doi:10.1038/s41467-020-19973-6.
  • Byrne A, Savas P, Sant S, Li R, Virassamy B, Luen SJ, Beavis PA, Mackay LK, Neeson PJ, Loi S. et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat Rev Clin Oncol. 2020;17(6):341–348. doi:10.1038/s41571-020-0333-y.
  • Jin K, Yu Y, Zeng H, Liu Z, You R, Zhang H, Liu C, Su X, Yan S, Chang Y. et al. CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer. Br J Cancer. 2022;126(11):1581–1588. doi:10.1038/s41416-022-01725-6.
  • Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1758835920937612. doi:10.1177/1758835920937612.
  • Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K. et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
  • Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39(33):3671–3681. doi:10.1200/JCO.21.00334.
  • Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–1087. doi:10.1093/annonc/mdz135.
  • Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D. Pembrolizumab in patients with programmed death ligand 1 – positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol. 2019;152(2):243–250. doi:10.1016/j.ygyno.2018.11.017.
  • Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 2019;5(3):393–401. doi:10.1001/jamaoncol.2018.6258.
  • Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 2015;75(18):3800–3811. doi:10.1158/0008-5472.CAN-15-1082.
  • Toker A, Nguyen LT, Stone SC, Yang SYC, Katz SR, Shaw PA, Clarke BA, Ghazarian D, Al-Habeeb A, Easson A. et al. Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma. Clin Cancer Res. 2018;24(22):5685–5696. doi:10.1158/1078-0432.CCR-18-0554.
  • Scognamiglio G, Capone M, Sabbatino F, Di Mauro A, Cantile M, Cerrone M, Madonna G, Grimaldi AM, Mallardo D, Palla M. et al. The ratio of GrzB+ – FoxP3+ over CD3+ T cells as a potential predictor of response to Nivolumab in patients with metastatic melanoma. Cancers Basel. 2021;13(10):2325. doi:10.3390/cancers13102325.
  • Eschweiler S, Clarke J, Ramírez-Suástegui C, Panwar B, Madrigal A, Chee SJ, Karydis I, Woo E, Alzetani A, Elsheikh S. et al. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nat Immunol. 2021;22(8):1052–1063. doi:10.1038/s41590-021-00958-6.
  • Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A. et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999–10008. doi:10.1073/pnas.1822001116.
  • Zhulai G, Oleinik E. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy. Scand J Immunol. 2022;95(3):e13129. doi:10.1111/sji.13129.
  • Tumino N, Martini S, Munari E, Scordamaglia F, Besi F, Mariotti FR, Bogina G, Mingari MC, Vacca P, Moretta L. et al. Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: functional analysis and expression of PD-1 receptor. Int J Cancer. 2019;145(6):1660–1668. doi:10.1002/ijc.32262.
  • Beldi-Ferchiou A, Lambert M, Dogniaux S, Vély F, Vivier E, Olive D, Dupuy S, Levasseur F, Zucman D, Lebbé C. et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7(45):72961–72977. doi:10.18632/oncotarget.12150.
  • Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, Peng J, Gao L, Liang X, Ma C. et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143–6153. doi:10.1038/onc.2017.209.
  • Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault M-C, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW. et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668. doi:10.1172/JCI99317.
  • Hasim MS, Marotel M, Hodgins JJ, Vulpis E, Makinson OJ, Asif S, Shih H-Y, Scheer AK, MacMillan O, Alonso FG. et al. When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer. Sci Adv. 2022;8(15):eabj3286. doi:10.1126/sciadv.abj3286.
  • Howard E, Hurrell BP, Helou DG, Quach C, Painter JD, Shafiei-Jahani P, Fung M, Gill PS, Soroosh P, Sharpe AH. et al. PD-1 blockade on tumor microenvironment-resident ILC2s promotes TNF-α production and restricts progression of metastatic melanoma. Front Immunol. 2021;12:733136. doi:10.3389/fimmu.2021.733136.
  • Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022;386(1):24–34. doi:10.1056/NEJMoa2109970.
  • Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425–1434. doi:10.1038/s41590-019-0512-0.
  • Sordo-Bahamonde C, Lorenzo-Herrero S, González-Rodríguez AP, Payer ÁR, González-García E, López-Soto A, Gonzalez S. LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia. Cancers Basel. 2021;13(9):2112. doi:10.3390/cancers13092112.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.